SLC5A2 and diabetic kidney disease: Based on this result, future clinical studies should explore the minimum protective dose of SGLT2 inhibitors that can be used without affecting the efficacy of the current standard doses of SGLT2 inhibitors in patients with DKD, which could improve safety and lead to more widespread application of SGLT2 inhibitors.